Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ionis Pharmaceuticals stock | 52.15

Own Ionis Pharmaceuticals stock in just a few minutes.


Fact checked

Ionis Pharmaceuticals, Inc is a biotechnology business based in the US. Ionis Pharmaceuticals shares (IONS) are listed on the NASDAQ and all prices are listed in US Dollars. Ionis Pharmaceuticals employs 817 staff and has a trailing 12-month revenue of around USD$940.5 million.

How to buy shares in Ionis Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Ionis Pharmaceuticals. Find the stock by name or ticker symbol: IONS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ionis Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$52.15, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ionis Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Ionis Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Ionis Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Ionis Pharmaceuticals's share price has had significant negative movement.

Its last market close was USD$52.15, which is 13.79% down on its pre-crash value of USD$60.49 and 32.63% up on the lowest point reached during the March crash when the shares fell as low as USD$39.32.

If you had bought USD$1,000 worth of Ionis Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$711.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$892.29.

Ionis Pharmaceuticals share price

Use our graph to track the performance of IONS stocks over time.

Ionis Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$52.15
52-week range USD$39.32 - USD$66.22
50-day moving average USD$49.9451
200-day moving average USD$54.8851
Wall St. target price USD$68.22
PE ratio 54.2584
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.916

Buy Ionis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ionis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ionis Pharmaceuticals price performance over time

Historical closes compared with the close of $52.15 from 2020-11-16

1 week (2020-11-24) 4.22%
1 month (2020-10-30) 11.08%
3 months (2020-09-01) -3.91%
6 months (2020-06-01) -8.25%
1 year (2019-11-29) -18.46%
2 years (2018-11-30) -10.53%
3 years (2017-12-01) -8.40%
5 years (2015-12-01) -15.72%

Is Ionis Pharmaceuticals under- or over-valued?

Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ionis Pharmaceuticals's P/E ratio

Ionis Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Ionis Pharmaceuticals shares trade at around 54x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Ionis Pharmaceuticals's EBITDA

Ionis Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$167.1 million.

The EBITDA is a measure of a Ionis Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Ionis Pharmaceuticals financials

Revenue TTM USD$940.5 million
Operating margin TTM 16.22%
Gross profit TTM USD$654.7 million
Return on assets TTM 3.2%
Return on equity TTM 7.87%
Profit margin 13.88%
Book value $9.873
Market capitalisation USD$6.6 billion

TTM: trailing 12 months

Shorting Ionis Pharmaceuticals shares

There are currently 8.1 million Ionis Pharmaceuticals shares held short by investors – that's known as Ionis Pharmaceuticals's "short interest". This figure is 3% up from 7.9 million last month.

There are a few different ways that this level of interest in shorting Ionis Pharmaceuticals shares can be evaluated.

Ionis Pharmaceuticals's "short interest ratio" (SIR)

Ionis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ionis Pharmaceuticals shares currently shorted divided by the average quantity of Ionis Pharmaceuticals shares traded daily (recently around 992379.29354446). Ionis Pharmaceuticals's SIR currently stands at 8.21. In other words for every 100,000 Ionis Pharmaceuticals shares traded daily on the market, roughly 8210 shares are currently held short.

However Ionis Pharmaceuticals's short interest can also be evaluated against the total number of Ionis Pharmaceuticals shares, or, against the total number of tradable Ionis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ionis Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ionis Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0694% of the tradable shares (for every 100,000 tradable Ionis Pharmaceuticals shares, roughly 69 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ionis Pharmaceuticals.

Find out more about how you can short Ionis Pharmaceuticals stock.

Ionis Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ionis Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Ionis Pharmaceuticals's total ESG risk score

Total ESG risk: 36.64

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ionis Pharmaceuticals's overall score of 36.64 (as at 10/01/2020) is pretty weak – landing it in it in the 62nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Ionis Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Ionis Pharmaceuticals's environmental score

Environmental score: 5.18/100

Ionis Pharmaceuticals's environmental score of 5.18 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Ionis Pharmaceuticals's social score

Social score: 26.17/100

Ionis Pharmaceuticals's social score of 26.17 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Ionis Pharmaceuticals's governance score

Governance score: 13.29/100

Ionis Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Environmental, social, and governance (ESG) summary

Ionis Pharmaceuticals, Inc was last rated for ESG on: 2020-10-01.

Total ESG score 36.64
Total ESG percentile 62.18
Environmental score 5.18
Environmental score percentile 9
Social score 26.17
Social score percentile 9
Governance score 13.29
Governance score percentile 9

Ionis Pharmaceuticals share dividends

We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months.

Ionis Pharmaceuticals share price volatility

Over the last 12 months, Ionis Pharmaceuticals's shares have ranged in value from as little as $39.32 up to $66.22. A popular way to gauge a stock's volatility is its "beta".

IONS.US volatility(beta: 1.49)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 1.4915. This would suggest that Ionis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ionis Pharmaceuticals overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with Genuity Science, Inc. for the discovery and development of various therapeutics across a range of approximately 20 diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site